The Chlamydia Market to Grow Positively at a Considerable CAGR During the Study Period (2019–2032), Assesses DelveInsight

Nevada (Las Vegas), United States, DelveInsight’s “Chlamydia – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Chlamydia market share of the individual therapies, current and forecasted Chlamydia market size from 2019 to 2032 segmented by seven major markets. The report also offers current Chlamydia therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chlamydia market.

Chlamydia Overview
Chlamydial infection, caused by Chlamydia trachomatis, is the most common bacterial sexually transmitted infection (STI). Age is a key predictor of risk for chlamydial infections, with the highest infection rates in women occurring between the ages of 15 and 24. Because most people with the virus are asymptomatic, it is frequently left untreated, increasing the risk of transmission and having disastrous health consequences for both sexes. Chlamydia symptoms differ depending on the individual and gender. Chlamydia symptoms typically appear two to six weeks after infection. Chlamydia symptoms differ between men and women. Chlamydia symptoms in men include pain while urinating, pain in the testicles, burning and itching in the urethra, and others. Women’s Chlamydia symptoms include vaginal discomfort and bleeding, abnormal vaginal discharge, pelvic pain, and others.

The Aptima Combo 2 Assay and the Xpert CT/NG were the first Chlamydia tests approved for extragenital diagnostic Chlamydia testing to detect the presence of the bacterium Chlamydia trachomatis via the throat and rectum. Previously, these assays were only approved for evaluating urine, vaginal, and endocervical materials. The availability of these two tests contributes to meeting an unmet public health need by allowing for additional screening.

Chlamydia Epidemiological Insights
The Chlamydia epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed incident cases, gender-specific cases, symptom-specific cases, and age-specific cases in the 7MM market covering the United States, EU-4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan from 2019 to 2032.

As per DelveInsight, there were approx 3.4 million Chlamydia diagnosed incident cases in the 7MM in 2021. Among EU5 countries, Germany had the highest diagnosed incident cases of Chlamydia in 2021.

Chlamydia Treatment Market
Chlamydia treatment reduces both harmful reproductive health issues and ongoing sexual transmission. Additionally, treating the sex partners lowers the risk of reinfection and infection of other partners. Furthermore, treating pregnant women frequently prevents C. trachomatis infection in newborns during delivery.

The Binx Health IO CT/NG Assay was recently approved by the FDA for use in point-of-care settings to aid in the more rapid and appropriate treatment of Chlamydia. Access to faster diagnostic results and appropriate therapies would be extremely beneficial in the fight against Chlamydia infections.

Promising Therapies in the Chlamydia Pipeline
• EVO100
• Chlamydia infection blockers (CIBs)
• VPI-201
• Salmonella-Based Vaccine

Discover more about Chlamydia therapies in the pipeline @ Chlamydia Drugs

Leading Companies Working in the Chlamydia Market
• Evofem Biosciences
• QureTechBio
• Vault Pharma
• Aeterna Zentaris
• Melinta Therapeutics
• Abera Bioscience
• Prokarium
• Blue willow Biologics
• Microbiotix
• Abivax

Learn more about the recent developments and breakthroughs in the Chlamydia market @ Chlamydia Clinical Trials

Chlamydia Market Dynamics
Chlamydia is by far the most common reportable STI, with a high occurrence rate that is expected to rise further in the future, necessitating treatment and thus boosting the Chlamydia market. A large number of asymptomatic cases go undetected, and as a result, the Chlamydia market could be much larger than expected. Furthermore, the Chlamydia treatment guidelines and screening recommendations have been updated. Furthermore, with the introduction of extremely sensitive and specific cost-effective diagnostic tools, diagnosis has become quick and simple, driving the Chlamydia market even further.

According to DelveInsight estimates, the Chlamydia market size was USD 59.5 million in 2021, which is further expected to increase by 2032.

However, the variety of chlamydia screening strategies makes it difficult for doctors and researchers to determine which are beneficial, which impacts the growth of the Chlamydia market. Furthermore, there has been a dearth of research linking chlamydial species to their final host. As a result, the Chlamydia market is experiencing slow growth.

Scope of the Chlamydia Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]
Key Chlamydia Companies: Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax, and others
Key Chlamydia Pipeline Therapies: EVO100, Chlamydia infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine, and others
Therapeutic Assessment: Chlamydia current marketed and emerging therapies
Chlamydia Market Dynamics: Chlamydia market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Chlamydia Market Access and Reimbursement

Table of Contents
1. Chlamydia Market Key Insights
2. Chlamydia Market Report Introduction
3. Chlamydia Market Overview at a Glance
4. Chlamydia Market Executive Summary
5. Disease Background and Overview
6. Chlamydia Treatment and Management
7. Chlamydia Epidemiology and Patient Population
8. Patient Journey
9. Chlamydia Emerging Drugs
10. 7MM Chlamydia Market Analysis
11. Chlamydia Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Chlamydia Market Drivers
15. Chlamydia Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187